



*This is an English translation of previously announced information on January 29 2021, that was only published in Swedish. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail.*

*NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR FOR AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, NEW ZEALAND OR OTHER JURISDICTION WHERE THE ANNOUNCEMENT, PUBLICATION OR DISTRIBUTION RELEASE WOULD BE ILLEGAL OR WOULD REQUIRE REGISTRATION OR OTHER ACTION.*

## **BRIGHTER AB (PUBL) CARRIES OUT UNIT ISSUE OF INITIALLY APPROXIMATELY SEK 117.8 M.**

The Board of Directors of Brighter AB (publ) (the "Company") has, with the support of authorization from the Annual General Meeting on 15 June 2020, decided to carry out an issue of a maximum of 98,145,231 units (the "Unit Issue"). The subscription period runs during the period 9-23 February 2021, or the period that may be caused by an extended official review of the prospectus. Each unit consists of one (1) share and one (1) free warrant TO6. The subscription price amounts to SEK 1.20 per unit, corresponding to SEK 1.20 per share. Through the Unit Issue, the Company will initially be provided with up to approximately SEK 117.8 million before issue costs. Upon full exercise of the warrants, Brighter can be provided with an additional sum up to approximately SEK 65.4 million before issue costs. The Unit Issue is covered by subscription and guarantee commitments up to a total amount of approximately SEK 94.2 million, corresponding to approximately 80% of the Unit Issue.

### **Background and motive**

Over the past year, Brighter has achieved a number of important operational goals in several countries to establish the Company's solutions for efficient data-driven healthcare. Our CE-approved Actiste® for insulin-treated diabetes has recently received market approval in Saudi Arabia and the United Arab Emirates. Actiste Mini®, which broadens our market potential for all diabetics, received CE approval this summer and in December received market approval in Saudi Arabia. Also in December, Brighter entered into two five-year distribution agreements with companies in Nigeria and Ghana regarding the Actiste® product portfolio. The distributors will, upon receipt of market approval, order at least 3,000 (Nigeria) and 1,500 (Ghana) subscriptions for a total initial value of approximately 3.5 MEUR. Brighter's two subsidiaries, Camanio and Nectarine Health, have developed well during the year. Camanio recently won a nationwide framework agreement with SKR (Sweden's Municipalities and Regions) regarding stationary security alarms and mobile security alarms. Nectarine Health prepared its market introduction for consumers in the USA, which is planned for the first half of 2021.

Over the past year, the composition of Brighter's Board has undergone several changes. Today, the board has the breadth of expertise and the stability needed for the company's continued commercialization phase. Brighter's commercialization process continues to go well. Despite the challenges the pandemic has caused in the healthcare industry, our continued investments in both market launches and development work are being carried out in accordance with the previously established strategy. Several factors also suggest that this work should be done with increased intensity. For example, the approvals in Saudi Arabia took place faster than the Company had previously anticipated. The more aggressive investment now recommended by the Board is taking place in order to achieve greater market penetration more quickly, and therefore requires the supply of expansion capital.



## Use of Issue proceeds

The proceeds from the Unit Issue, as well as proceeds from a possible Over-allotment Issue, shall be distributed proportionally in the following areas:

- Market investments - 50%
- Research & Development - 15%
- Production - 35%

## Terms for the Unit Issue

The issue comprises a maximum of 98,145,231 units upon full subscription, each consisting of one (1) share and one (1) free warrant series TO6. The record date at Euroclear Sweden AB for determining who will receive unit rights in the issue is 5 February 2021. The terms of the Unit Issue mean that shareholders in the Company receive three (3) unit rights for each one (1) share held. Seven (7) unit rights are required to subscribe for one (1) unit at a subscription price of SEK 1.20 per unit, which corresponds to a subscription price per share of SEK 1.20. Unit rights that are not exercised during the subscription period become invalid and lose their value.

Upon full subscription, the Unit Issue entails an increase of the share capital by a maximum of SEK 4,907,261.55, from SEK 11,450,277.00 to SEK 16,357,539, through a new issue of a maximum of 98,145,231 shares, each with a quota value of 0.05 SEK. The newly issued shares will then constitute approximately 30% of all outstanding shares. Existing shareholders who do not subscribe for their eligible shares will, upon full subscription, see their ownership in the Company diluted to a corresponding degree.

Allocation shall be made as follows. In the first instance, allocation shall take place to the company's previous shareholders who have stated their shareholding on the registration date as of the record date. In the event of over-subscription, the allocation takes place pro rata in relation to the number of shares held per the record date and to the extent that this cannot be done, by drawing lots. Ultimately, the remaining shares will be allocated to persons who have guaranteed the issue in accordance with their guarantee commitments.

## Terms for subscription of shares through warrants TO6

Three (3) warrants TO6 are required to subscribe for one (1) new share at a subscription price corresponding to the volume-weighted average price (VWAP) measured during the period of fifteen (15) trading days ending two (2) banking days before the subscription period begins, however, a minimum of SEK 1.20 and a maximum of SEK 2.00. Subscription of shares with the support of warrants TO6 takes place during the period 18 October - 1 November 2021. Subscription of shares through warrants TO6 entails an increase, upon full subscription, of the share capital by an additional SEK 1,635,753.85. Upon full utilization, Brighter will receive an additional minimum of SEK 39,258,092.40 and a maximum of SEK 65,430,154.00 before issue costs. The company will work to ensure that TO6 is admitted to trading during the term of the option.

## Over-allotment issue

In the event of an over-subscription, the Board may decide on an over-allotment issue of a maximum of 29,443,569 units at the same subscription price as in the Unit Issue. The purpose of the over-allotment issue is, in the first instance, to enable any professional and institutional investors to be established as major owners in the Company, and in the second instance to satisfy the wishes of the persons who before the commencement of the subscription period have left or may make subscription commitments without unit rights, and, in the third place, take advantage of the opportunity to provide the Company with additional working capital. Upon full utilization of the over-allotment issue, the Company will receive an additional SEK 35,332,283.16. In addition, the Company will also receive, in the event of full exercise of the attached warrants TO6, a minimum 11,777,428 SEK and a maximum of 19,629,046 SEK.



## EU growth-prospectus

Full information on the Unit Issue will be presented in an EU growth-prospectus, which will be published before the start of the subscription period.

## Subscription and warranty commitments

The Unit Issue is covered by subscription and guarantee commitments up to a total amount of approximately SEK 94.2 million, corresponding to approximately 80% of the Unit Issue. Subscription commitments amount to approximately SEK 1.6 million (approximately 1.3% of the Unit Issue) that has been submitted by the Company's acting-CEO Christer Trägårdh, and SEK 1.0 million from additional shareholders (corresponding to 0.9%). In addition, the Company has received guarantee commitments of approximately SEK 91.6 million (approximately 77.8% of the Unit issue).

Further information regarding the parties who have entered into warranty commitments will be contained in the above-mentioned prospectus.

## Preliminary schedule for the Unit Issue

|  |  |
|--|--|
| The last day for trading in the Company's shares, including the right to receive unit rights | 3 February 2021                        |
| First day for trading in the Company's share excluding the right to receive unit rights      | 4 February 2021                        |
| Record date for participation in the Unit Issue  | 5 February 2021                        |
| Estimated date for publication of EU growth-prospectus                                       | 8 February 2021                        |
| Subscription period in the Unit Issue  | 9-23 February 2021                     |
| Trade in unit rights (UR)  | 9-19 February 2021                     |
| Trade in Paid Subscription Units (BTU)   | 9 February 2021 – around week 13, 2021 |
| Preliminary date for publication of results in the Unit Issue                                | 25 February 2021                       |

## Issuing institute

Eminova Fondkommission AB acts as an issuer to the Company in connection with the Unit Issue.

For further information, please contact:

Investor Relations

[IR@brighter.se](mailto:IR@brighter.se)

Christer Trägårdh, Acting CEO

[christer.tragardh@brighter.se](mailto:christer.tragardh@brighter.se)

Certified Adviser

Brighter's Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, [adviser@eminova.se](mailto:adviser@eminova.se),

[www.eminova.se](http://www.eminova.se).

## About Brighter AB (publ)

Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for



# Brighter

data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Follow us on:



Brighter AB (publ)

Borgarfjordsgatan 18  
SE-164 40 Kista  
Sweden

+46 (0)8 550 088 20  
info@brighter.se  
www.brighter.se